The Development of Novel Therapies for Rheumatoid Arthritis.
The Development of Novel Therapies for Rheumatoid Arthritis.
复制标题
DOI：
10.1517/13543776.18.7.723
复制
发表时间：
2008-07
影响因子：
6.6
通讯作者：
Wang D
中科院分区：
文献类型：
--
作者：
Quan LD;Thiele GM;Tian J;Wang D
类风湿性关节炎 (RA) 是一种慢性、全身性炎症性疾病，影响全世界大约 0.5% 至 1% 的成年人，通常会导致关节破坏和生活质量严重受损。 RA被认为是一种病因不明的自身免疫性疾病。最近揭示了 RA 的许多致病途径，这导致了各种新疗法的开发。目前RA的治疗包括4类：非甾体抗炎药（NSAIDs）、糖皮质激素、非生物缓解病情抗风湿药（DMARDs）和生物DMARDs。在这篇综述中，我们将讨论抗风湿疗法的一些最新进展。使用 SciFinder Scholar 和 PubMed 作为主要搜索工具，我们评估了各种新开发的 RA 疗法。在每个药物类别下，重点关注药物的作用方式、限制以及专利检索中的新候选药物。这些行之有效的疗法将仅进行简要回顾。过去20年，新疗法的开发大部分是DMARD，尤其是生物DMARD。随着新途径的发现和药物输送策略的应用，预计该研究领域将出现更多增长。
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that affects approximately 0.5 to 1 percent of the adults worldwide and commonly results in joint destruction and significant impairment in the quality of life. RA is considered as an autoimmune disease with unknown etiology. Many pathogenic pathways of RA have been revealed recently, which led to development of various novel therapies. The current treatments of RA include 4 categories: non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, non-biologic disease-modifying anti-rheumatic drugs (DMARDs) and biologic DMARDs. In this review, we will discuss some of the most recent development in antirheumatic therapies. Using SciFinder Scholar and PubMed as main searching tools, we evaluated various newly developed therapies for RA. Under each drug category, emphases are placed on the mode of action, limitation of the drugs and new drug candidates from the patents search. Those well-established therapies will only be reviewed briefly. During the past 20 years, most of the development of new therapies is in DMARDs, especially biological DMARDs. With the discovery of new pathways and the application of drug delivery strategies, more growth is anticipated in this research field.
登录
查看更多内容
影响因子：
--
作者：
Brown, SL;Greene, MH;Braun, MM
通讯作者：
Braun, MM
影响因子：
2.3
作者：
Bresnihan, B;Cunnane, G
通讯作者：
Cunnane, G
影响因子：
158.5
作者：
Bombardier, C;Laine, L;Weaver, A
通讯作者：
Weaver, A
影响因子：
27.4
作者：
Askling, J;Fored, CM;Feltelius, N
通讯作者：
Feltelius, N
影响因子：
4.8
作者：
Bossard, MJ;Tomaszek, TA;Levy, MA
通讯作者：
Levy, MA